Indeed, in patients with sporadic MTC, between 12.6% and 40.9% harbor RAS mutations [58,61,62], and 68% of RET-negative MTC patients carry RAS mutations in comparison to 2.5% of RET-positive MTC patients [58]. Here, RET is linked to medullary thyroid gland carcinoma.